A twice-yearly shot could help end AIDS. But how can people access it?

The drug has been called a profound advancement in medicine but getting it to those who need it is a “missing piece in the puzzle,” experts say.

A twice-yearly injection was 96 per cent effective in preventing HIV infections in men, according to results published last week about a drug that’s been called the closest the world has ever come to an HIV vaccine.

The injection was significantly more effective than the daily oral pill PrEP (pre-exposure prophylaxis) in what researchers called a “profound advancement in medicine”.

Called lenacapavir, it is already sold under the brand name Sunlenca to treat HIV infections in the US, Canada, Europe and elsewhere. It was previously shown to be 100 per cent effective in preventing HIV infections in a study of women.

“This is so far superior to any other prevention method we have, that it’s unprecedented,” said Winnie Byanyima, executive director of UNAIDS.

She credited Gilead for developing the drug but said the world’s ability to stop AIDS hinges on its use in at-risk countries.

Drugmaker Gilead said it will allow cheap, generic versions to be sold in 120 poor countries with high HIV rates, mostly in Africa, Southeast Asia, and the Caribbean.

But it has excluded nearly all of Latin America, where rates are far lower but increasing, sparking concern the world is missing a critical opportunity to stop the disease.

Number of AIDS deaths at lowest since peak

In a report issued to mark World AIDS Day on Sunday, UNAIDS said that the number of AIDS deaths last year, an estimated 630,000, was at its lowest since peaking in 2004, suggesting the world is now at “a historic crossroads” and has a chance to end the epidemic.

While there are other ways to guard against infection, like condoms, daily pills, vaginal rings, and bi-monthly shots, experts say the Gilead twice-yearly shots would be particularly useful for marginalised people often fearful of seeking care, including gay men, sex workers, and young women.

“It would be a miracle for these groups because it means they just have to show up twice a year at a clinic and then they’re protected,” said UNAIDS’ Byanyima.

Such was the case for Luis Ruvalcaba, a 32-year-old man in Guadalajara, Mexico, who participated in the latest published study. He said he was afraid to ask for the daily prevention pills provided by the government, fearing he would be discriminated against as a gay man.

Because he took part in the study, he’ll continue to receive the shots for at least another year.

Push to make drug available in Latin American countries

“In Latin American countries, there is still a lot of stigma, patients are ashamed to ask for the pills,” said Dr Alma Minerva Pérez, who recruited and enrolled a dozen study volunteers at a private research centre in Guadalajara.

The extent to which the shots will be widely available in Mexico through the country’s healthcare system isn’t yet known.

Health officials declined to comment on any plans to buy Sunlenca for its citizens; daily pills to prevent HIV were made freely available via the country’s public health system in 2021.

Byanyima said other countries besides Mexico that took part in the research were also excluded from the generics deal, including Brazil, Peru, and Argentina.

“To now deny them that drug is unconscionable,” she said.

In a statement, Gilead said it has “an ongoing commitment to helping enable access to HIV prevention and treatment options where the need is the greatest”.

Among the 120 countries eligible for the generic version are 18 mostly African countries that comprise 70 per cent of the world’s HIV burden.

The drugmaker said it is also working on establishing “fast, efficient pathways to reach all people who need or want lenacapavir for HIV prevention”.

On Thursday, 15 advocacy groups in Peru, Argentina, Ecuador, Chile, Guatemala and Colombia wrote to Gilead, asking for generic Sunlenca to be made available in Latin America, citing the “alarming” inequity in access to new HIV prevention tools while infection rates were rising.

While countries including Norway, France, Spain, and the US have paid more than $40,000 (€38,000) per year for Sunlenca, experts have calculated it could be produced for as little as $40 (€38) per treatment once generic production expands to cover 10 million people.

Dr Salim Abdool Karim, an AIDS expert at South Africa’s University of KwaZulu-Natal, said he had never seen a drug that appeared to be as effective as Sunlenca in preventing HIV.

“The missing piece in the puzzle now is how we get it to everyone who needs it,” he said.

Read the full article here